Information For Patients
What is CAR T-cell treatment?
This section provides information on CAR T-cell therapy and its treatment phases, accompanied by videos explaining various aspects of the therapy.
The content is compiled by T2EVOLVE, an EU-funded initiative that aims to accelerate the development of CAR T-cell therapy in Europe, ensuring patients have access to cutting-edge care while supporting its integration into healthcare systems.
T2EVOLVE collaborated with the Working Group of Patients and Caregivers (WGPC), EuroGCT, Acute Leukemia Advocate Network (ALAN), Myeloma Patients Europe (MPE), and Lymphoma Coalition to develop these videos, ensuring they reflect patient perspectives, educational insights, and practical guidance for understanding CAR T-cell therapy.
CAR T-cell therapy explained
CAR T-cell therapy is a novel form of immunotherapy to treat cancer using a patient’s own T-cells which are collected via leukapheresis or T-cells from a donor. In Europe, patients can be treated with CAR T-cell therapy as part of standard of care or by participating in a clinical trial.
Animation from Mofitt Cancer Center to explain CAR T-cell therapy. For more from Mofitt Cancer Center, click here.
Animation from the Children’s Hospital of Philadelphia. For more from the hospital, click here.
Currently, only CAR T-cell therapies using patients’ own T-cells are available as standard of care to treat hematologic cancers in Europe (i.e. not as part of a clinical trial). Although often only a single infusion with CAR T-cells is needed, the treatment trajectory is intensive and consists of several treatment phases.
Explainer videos produced by T2EVOLVE
How to identify reliable information on CAR T-cell therapy using the internet
This explainer video for patients shares basic information about CAR T-cell therapy and how to identify reliable information online.
Who is eligible for CAR T-cell Therapy?
CAR T-cell therapy isn’t suitable for every patient, making it essential to understand the factors determining eligibility. In this compelling new video, a patient shares his heartfelt personal journey with CAR T-cell therapy, while leading hematologists break down the critical medical considerations that influence treatment candidacy.
Watch now to gain valuable insights into the eligibility process and the nuances of this innovative treatment.
Long-term infection risk after CAR T-cell therapy
After receiving CAR T-cell therapy, patients may face an increased risk of infections that can persist for months, and sometimes even years after treatment.
In this video, leading hematologists explain how infection risks can evolve over time. A patient also shares his personal experience of the journey after treatment.
Watch the video to gain valuable insights into infection risks following CAR T-cell therapy.
Additional resources
The CAR T-CELL THERAPY/CLINICAL TRIAL JOURNEY: A Guide for Patients and Carers
The NA-ATTC is pleased to offer The CAR T-Cell Therapy Clinical Trial Journey – A Guide for Patients and Carers in partnership with Autolus Therapeutics. This Guide is intended for people who are either considering enrolling in or are already enrolled in a CAR T-cell therapy clinical trial. It contains information for both patients and those who care for them (92 pages).
